Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Authors
Keywords
-
Journal
Current Pain and Headache Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-24
DOI
10.1007/s11916-023-01183-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor
- (2023) Gabriel Gárate et al. ANNALS OF NEUROLOGY
- Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
- (2023) Katharina Kaltseis et al. BMC Neurology
- Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
- (2023) Luigi Francesco Iannone et al. CEPHALALGIA
- Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey
- (2023) Purnima Pathak et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
- (2023) Andreas A. Argyriou et al. EUROPEAN JOURNAL OF NEUROLOGY
- An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
- (2023) Francesca Schiano di Cola et al. EUROPEAN JOURNAL OF NEUROLOGY
- Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics
- (2023) Alicia Gonzalez-Martinez et al. Gastroenterologia y Hepatologia
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study
- (2023) Hyoung Cheol Lee et al. NEUROLOGICAL SCIENCES
- Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
- (2023) Lucas Hendrik Overeem et al. Frontiers in Neurology
- Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
- (2023) Shiho Suzuki et al. Frontiers in Neurology
- A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
- (2023) Ja Bin Hong et al. Pharmaceuticals
- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
- (2022) Luigi Francesco Iannone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
- (2022) Simona Guerzoni et al. NEUROLOGICAL SCIENCES
- Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction
- (2022) Kuan-Po Peng et al. PAIN
- Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
- (2022) Soonwook Kwon et al. CEPHALALGIA
- Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments
- (2022) Chia-Kuang Tsai et al. Current Pain and Headache Reports
- CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
- (2022) Yen-Feng Wang et al. Current Pain and Headache Reports
- Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
- (2022) Modar Khalil et al. EUROPEAN JOURNAL OF NEUROLOGY
- Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
- (2022) Hannah Schenk et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
- (2022) Maurice T. Driessen et al. JOURNAL OF HEADACHE AND PAIN
- Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
- (2022) Hauke Basedau et al. eLife
- Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
- (2022) Magdalena Nowaczewska et al. Frontiers in Neurology
- Salivary CGRP and erenumab treatment response: towards precision medicine in migraine
- (2022) Alicia Alpuente et al. ANNALS OF NEUROLOGY
- Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide ( CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
- (2022) Alicia Gonzalez‐Martinez et al. EUROPEAN JOURNAL OF NEUROLOGY
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
- (2022) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
- (2022) Michael Lowe et al. JOURNAL OF HEADACHE AND PAIN
- Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study
- (2022) Ilaria Cetta et al. NEUROLOGICAL SCIENCES
- Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
- (2022) Ann M. Murray et al. Current Pain and Headache Reports
- Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
- (2022) Tsubasa Takizawa et al. BMC Neurology
- Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab
- (2022) Todd J. Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
- (2021) Robert Belvís et al. JOURNAL OF HEADACHE AND PAIN
- Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
- (2021) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- (2021) María Del Pilar Briceño-Casado et al. European Journal of Hospital Pharmacy-Science and Practice
- Predictors of response to erenumab after 12 months of treatment
- (2021) Carlo Baraldi et al. Brain and Behavior
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinic and genetic predictors in response to erenumab
- (2021) Chiara Zecca et al. EUROPEAN JOURNAL OF NEUROLOGY
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
- (2021) Jean Schoenen et al. Frontiers in Neurology
- PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
- (2021) Messoud Ashina et al. Pain Management
- Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
- (2020) Anne-Sophie Wattiez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Gut-brain Axis and migraine headache: a comprehensive review
- (2020) Mahsa Arzani et al. JOURNAL OF HEADACHE AND PAIN
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
- (2019) Ivan Urits et al. Current Pain and Headache Reports
- Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain
- (2019) Meredith Barad et al. REGIONAL ANESTHESIA AND PAIN MEDICINE
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search